The
U.S. International Trade Commission's (ITC) order will go into
effect on Dec. 26, barring imports and sales of Apple Watches
that use patent-infringing technology for reading blood-oxygen
levels. Apple has included the pulse oximeter feature in its
smart watches starting with its Series 6 model in 2020.
U.S. Trade Representative Katherine Tai decided not to reverse
the ban following careful consultations, and the ITC's decision
became final on Dec. 26, the agency said in its decision.
Apple can, however, appeal the ban to the U.S. Court of Appeals
for the Federal Circuit.
The company has paused the sales of its Series 9 and Ultra 2
smartwatches in the United States since last week. The ban does
not affect Apple Watch SE, a less expensive model, which will
continue to be sold. Previously sold watches will not be
affected by the ban.
Masimo has accused Apple of hiring away its employees, stealing
its pulse oximetry technology and incorporating it into the
popular Apple Watch.
A jury trial on Masimo's allegations in California federal court
ended with a mistrial in May. Apple has separately sued Masimo
for patent infringement in federal court in Delaware and has
called Masimo's legal actions a "maneuver to clear a path" for
its own competing smart watch.
A presidential administration has not vetoed an ITC ruling since
2013, when President Barack Obama's administration overturned an
import ban on Apple's iPhones and iPads in the company's patent
dispute with Samsung.
The Biden administration in February chose not to veto a
separate import ban on Apple Watches based on a
patent-infringement complaint from medical technology company
AliveCor. The ITC has placed the ban on hold for other reasons.
Apple's wearables, home and accessory business, which includes
the Apple Watch, AirPods earbuds and other products, brought in
$8.28 billion in revenue during the third quarter of 2023,
according to a company report.
(Reporting by Blake Brittain in Washington and Samrhitha
Arunasalam in Bengaluru; Editing by Matthew Lewis and Anil
D'Silva)
[© 2023 Thomson Reuters. All rights
reserved.]
Copyright 2022 Reuters. All rights reserved. This material may
not be published, broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|